Background: Memory declines more rapidly with age in apolipoprotein E (APOE) ε4 carriers than in APOE ε4 noncarriers, and APOE ε4 homozygotes' cognitive performances correlate with stressors. These changes could represent presymptomatic disease in some, despite their youth.
A POLIPOPROTEIN E (APOE) ε4 reduces the median age at Alzheimer disease (AD) onset by gene dose from 84 years in APOE ε4 noncarriers to 68 years in APOE ε4 homozygotes. [1] [2] [3] [4] [5] [6] Breitner et al, 4 for example, found a disproportionately high number of APOE ε4 homozygotes in a population with AD onset between the ages of 55 and 75 years. Since 1994 we have been enrolling and following up a cohort of healthy APOE ε4 homozygotes aged 50 to 69 years at entry, demographically matched to APOE ε3/4 heterozygotes and APOE ε4 noncarriers. As a group, these APOE ε4 carriers have reduced cerebral metabolism in the same brain regions as patients with probable AD, which correlates with the APOE ε4 gene dose 7 and is progressive. 8 Memory declines more rapidly with age in APOE ε4 carriers than in APOE ε4 noncarriers, 9 and the APOE ε4 homozygotes' cognitive performances correlate with stressors, including fatigue 10 and anxiety. 11 These changes could represent presymptomatic disease in some, despite their youth. We postulated, therefore, that cognitively healthy APOE ε4 homozygotes must be at greater risk for neuropsychological decline than APOE ε4 heterozygotes and noncarriers preceding clinical conversion to mild cognitive impairment (MCI) and AD as they age into their 60s.
METHODS

STRATEGY
We tested the hypothesis that there is a higher rate of neuropsychological decline among APOE Author Affiliations are listed at the end of this article.
ε4 homozygotes than APOE ε4 heterozygotes and noncarriers during the seventh decade of life. Clinical criteria for MCI 12, 13 and AD 14 emphasize but do not operationally define cognitive domain decline, so we created objective criteria for test score, test (some tests have multiple scores), and cognitive domain decline (a decline on at least 2 tests of that cognitive domain). We analyzed 2 age-decile groups (sixth and seventh decades) for emergent patterns of decline and the influence of APOE on such patterns.
STUDY PARTICIPANTS, GENOTYPING, AND SCREENING
Participants were 50 to 69 years old at entry and were identified through local newspaper advertisements that requested healthy individuals who had a first-degree relative with AD. 9 Genetic determination of APOE allelic status was performed using a polymerase chain reaction-based assay. 15 Each APOE ε4 homozygote was matched to 1 APOE ε4 heterozygote (APOE ε3/4 genotype) and 2 APOE ε4 noncarriers for sex, age (within 3 years), and educational level (within 2 years). Screening tests included medical history, neurologic examination, Folstein Mini-Mental State Examination, Hamilton Depression Rating Scale, and the Structured Psychiatric Interview for Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised). 16 None met criteria for MCI, 12,13 AD, 14 any other form of dementia, or major depressive disorder. 16 Those who completed at least 2 epochs of testing were included.
DEFINING DECLINE
Test Score Decline
A 4-hour battery of neuropsychological tests 17 was administered approximately every 2 years. Test-retest changes were calculated for each score on each test between each pair of consecutive epochs. We assumed that disease-related decline would manifest as interepoch decline, although we realize that longer decline intervals are possible. Decline between consecutive epochs that exceeded 2 SDs beyond decline of the entire cohort was defined as abnormal.
Test Decline
For tests with multiple scores, only a single test score was required to define test decline. For example, only 1 of the 3 scores used from the Auditory Verbal Learning Test (AVLT) 17 (shortterm delayed recall, long-term delayed recall, and percent recall) was required for a diagnosis of AVLT decline.
COGNITIVE DOMAINS
Five cognitive domains were defined. Four reflected intellectual skills: executive, memory, language, and spatial. The fifth was a behavioral domain, since depression and paranoia frequently occur in early AD. Tests that comprised these domains were as follows: Additionally, all received the WAIS-R Information and Digit Symbol Substitution, Mattis Dementia Rating Scale, Wechsler Memory Scale Orientation, and the Functional Assessment and Instrumental Activities of Daily Living Questionnaires. Subjective assessment of cognitive and behavioral change during the preceding year was obtained from a close observer (typically a spouse) and the participant using previously unpublished questionnaires.
Cognitive domain decline was defined as a decline on 2 or more tests within that domain. From these definitions, the following 5 decline categories were created: Comparisons between groups for normally distributed data were made using either analysis of variance or 2-sample t tests for continuous data and the 2 or Fisher exact test for categorical data. The Kruskal-Wallis or Wilcoxon rank sum test was used for scores that were not normally distributed. All reported P values are 2-tailed. Participants who were evaluated for cognitive difficulties arising any time after at least 1 epoch of testing and who fulfilled published criteria for MCI 12, 13 or AD 14 were considered clinical converters.
RESULTS
DEMOGRAPHICS
Of 268 participants who enrolled, 214 completed at least 2 epochs of testing with a mean±SD duration of observation of 56.7±30.1 months (median, 53.0 months) and were included in this analysis. Compared with participants, dropouts were less likely to report a family history of dementia in a first-degree relative (P Ͻ .001, 2 test), but no differences were found in age, sex, educational level, or score on any psychometric measure. From the entry epoch, the mean ± SD duration was 23.9±5.2 months to epoch 2, 51.2±11.2 months to epoch 3, 74.9±8.4 months to epoch 4, 96.8±9.9 months to epoch 5, 110.5±12.9 months to epoch 6, and 125.8±1.3 months to epoch 7. Table 1 summarizes the demographic data of the participants. There were 43 APOE ε4 homozygotes, including 33 aged 50 through 59 years and 10 aged 60 through 69 years at entry. The mean±SD MiniMental State Examination score at entry for the entire cohort was 29.6±0.7, which did not differ among the 3 genetic subgroups for those aged 50 through 59 years (P =.37) or 60 through 69 years (P=.29; analysis of variance). The frequency of a first-degree relative was slightly lower among the APOE ε4 noncarriers (who otherwise had a second-degree relative with dementia). A total of 126 showed decline on only 1 test in 1 (n=63, category 2) or more domains (n=63, category 3), and 40 showed decline on 2 or more tests in 1 (n = 35, category 4) or multiple domains (n = 5, category 5). Single-domain decline (category 4) affected memory in 14, behavior in 8, executive skills in 7, and language in 6 participants. Those who experienced executive and language decline were younger than the other singledomain groups (P Ͻ .001; 2-sample t tests). None had single-domain spatial decline. Five had multidomain decline (category 5) that involved spatial in 4, executive skills and memory each in 3, and language in 2. Six participants developed MCI (amnestic in 5 and visual in 1), and 1 developed AD. Among the 6 patients with MCI, 3 progressed to AD (autopsy obtained with AD confirmation in 1 to date). All were in their 60s at the time of symptomatic conversion. Mean±SD time to clinical presentation after entry was 54.4±35.7 months, and mean±SD age at diagnosis was 64.3±3.7 years. Five were APOE ε4 homozygotes (11.9% of all the APOE ε4 homozygotes enrolled), 1 was an APOE ε4 heterozygote (2.0% of APOE ε4 heterozygotes enrolled), and 1 was an APOE ε4 noncarrier (1.0% of APOE ε4 noncarriers enrolled) (P=.008; Fisher exact test). Stated differently, 5 of 7 converters (71.4%) were homozygotes even though homozygotes constituted only 20.0% of the cohort (43/214).
PATTERNS OF COGNITIVE DECLINE
APOE 4 AND AGE INFLUENCES ON DECLINE PATTERNS
OUTCOMES AFTER THE DECLINE EPOCH
COMPARISON OF ENTRY PERFORMANCES BASED ON DECLINE PATTERNS
Baseline performances were compared between those who did not decline and the other 4 categories of decline ( Table 4) . Compared with those who did not decline (category 1), few differences occurred overall, reconfirming the truly incident nature of observed decline. Those who experienced multidomain, language, and memory decline had lower scores on spatially oriented tests that encompassed memory and spatial domains. Those who experienced multidomain and language decline additionally had lower scores on the Boston Naming Test. Mean scores for all tests at entry were nonetheless well within normal limits.
COMMENT
Our results show that by the time they reach their early 60s, many APOE ε4 homozygotes experience cognitive domain decline that precedes the clinical diagnosis of MCI or AD. The number of clinical converters in this study was small, but they also were mostly APOE ε4 homozygotes. Our findings are consistent with the original formulation of Corder et al 1 and with previous casecontrol studies, 1,2 epidemiologic studies, 3, 6 and metaanalyses 5 that have suggested a gene dose-related earlier age at AD onset.
Memory was normal at entry, but decline on the incident memory test predicted subsequent further decline. Baseline performances in those who declined on the multidomain, memory, and language tests were characterized by lower memory and spatial domain performance than those who did not decline, a neuropsychological pattern that typifies AD and suggests that AD may have already started in these individuals despite their normal entry test scores. Because decline was detected in individuals and not simply at a group level, our data point out the potential utility of longitudinal change as a clinically meaningful harbinger of impending symptomatic conversion when baseline neuropsychological scores fail to reveal impairment. Before addressing our results further, the limitations of this study must be weighed. Although this study capitalized on rigorously defined, prospectively tested decline categories, nearly every one of our decisions in creating these definitions can be questioned: the 2-SD threshold for abnormal decline, use of a 2-year interepoch change, choice of tests, choice of test scores, choice of domains, and the categories of decline. The number of clinical converters to date is small. Even so, our definitions of longitudinal cognitive decline were more sensitive than cross-sectional measures in predicting further decline or clinical conversion, and they supported our prediction that homozygotes who are at the highest risk for AD would experience the greatest decline preclinically as well as clinical conversion to MCI and AD. Our ongoing longitudinal study will determine the extent to which our baseline measurements and longitudinal declines predict conversion in larger samples. Studies in subsets of these individuals may permit us to determine the extent to which these declines predict rates of conversion in bioimaging and other biomarker measurements of AD progression and ultimately the extent to which these declines predict rates of conversion to the neuropathologic diagnosis of AD.
Many longitudinal aging studies are currently being performed in the United States and elsewhere, and an approach to the rational interpretation of longitudinal decline that precedes symptomatic diagnosis is needed, which is underscored by our observed high frequency of test score decline. Ours is one such approach. Presymptomatic individuals with neuropsychologically documented longitudinal decline clearly exist but likely constitute different groups, as shown by our results. Further supporting this concept, Storandt et al 18 recently com- 
